The genomic landscape of response to EGFR blockade in colorectal cancer
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Colorectal cancer is the third most common cancer worldwide, with 1.2 million patients diagnosed annually. In late-stage colorectal cancer, the most commonly used targeted therapies are the monoclonal antibodies cetuximab and panitumumab, which prevent epidermal growth factor receptor (EGFR) activation. Recent studies have identified alterations in KRAS and other genes as likely mechanisms of primary and secondary resistance to anti-EGFR antibody therapy. Despite these efforts, additional mechanisms of resistance to EGFR blockade are thought to be present in colorectal cancer and little is known about determinants of sensitivity to this therapy. To examine the effect of somatic genetic changes in colorectal cancer on response to anti-EGFR antibody therapy, here we perform complete exome sequence and copy number analyses of 129 patient-derived tumour grafts and targeted genomic analyses of 55 patient tumours, all of which were KRAS wild-type. We analysed the response of tumours to anti-EGFR antibody blockade in tumour graft models and in clinical settings and functionally linked therapeutic responses to mutational data. In addition to previously identified genes, we detected mutations in ERBB2, EGFR, FGFR1, PDGFRA, and MAP2K1 as potential mechanisms of primary resistance to this therapy. Novel alterations in the ectodomain of EGFR were identified in patients with acquired resistance to EGFR blockade. Amplifications and sequence changes in the tyrosine kinase receptor adaptor gene IRS2 were identified in tumours with increased sensitivity to anti-EGFR therapy. Therapeutic resistance to EGFR blockade could be overcome in tumour graft models through combinatorial therapies targeting actionable genes. These analyses provide a systematic approach to evaluating response to targeted therapies in human cancer, highlight new mechanisms of responsiveness to anti-EGFR therapies, and delineate new avenues for intervention in managing colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“EGFR somatic sequence changes, including G465R, G465E, S468R and S492R, located at the extracellular domains (ECDs) of the EGFR-mAb interaction interface, confer resistance to cetuximab and panitumumab by preventing mAb binding [10, 67, 68].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, in late-line therapy, only 12–17% of patients have durable responses to anti-EGFR monotherapy [4]”
From Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer (2020) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Gene mutations downstream of the EGFR signalling pathway, including RAS/RAF/MEK and PI3K/AKT/mTOR, significantly contribute to drug resistance [9–11].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [10]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This is supported by our observation, consolidated after monitoring hundreds of mCRC PDXs exposed to cetuximab (10, 25, 27, 29, 30), that complete responses are exceptional events.”
From Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer (2023) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“A growing number of studies suggest that mutations in the extracellular domain (ECD) of the EGFR, such as S492R, G465E, R451C and K467T, prevent binding cetuximab and make CRC resistant to anti-EGFR mAbs [141,142,143,144].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [144]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Needleman, S. B., & Wunsch, C. D. (1970) · Journal of Molecular Biology · doi:10.1016/0022-2836(70)90057-4 · Cited by 11,288 · cited 1×
“Sequence reads were aligned against the human reference genome (version hg18) using ELAND with additional realignment of select regions using the Needleman-Wunsch method 35 .”
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“A mutation in the tumour was identified as a candidate somatic mutation only when (1) distinct paired reads contained the mutation in the tumour, (2) the number of distinct paired reads containing a particular mutation in the tumour was at least 2% of the total distinct read pairs for targeted analyses and 10% of read…”
Self-citationThe Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Self-citationPDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Duensing, A., McGreevey, L., Chen, C.-J., Joseph, N., Singer, S., Griffith, D. J., Haley, A., Town, A., et al. (2003) · Science · doi:10.1126/science.1079666 · Cited by 2,301
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citationEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 6×
“Common CRC driver genes were identified at expected frequencies in the tumours analysed (Supplementary Tables 3–5).”
InfluentialSelf-citationThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
Coiffier, B., Osmanov, E. A., Hong, X., Scheliga, A. A. D. S., Mayer, J., Offner, F., Rule, S. A., Teixeira, A., Walewski, J. A., Vos, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045 · Cited by 1,631
Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Diverse somatic mutation patterns and pathway alterations in human cancers
Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., Yue, P., Haverty, P. M., Bourgon, R., Zheng, J., et al. (2010) · Nature · doi:10.1038/nature09208 · Cited by 1,027
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941
Self-citationBertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939
Self-citationComparative lesion sequencing provides insights into tumor evolution
Jones, S., Chen, W.-D., Parmigiani, G., Diehl, F., Beerenwinkel, N., Antal, T., Traulsen, A., Nowak, M. A., Siegel, C., Velculescu, V. E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712345105 · Cited by 818 · cited 1×
“IRS2 expression in 100tumourgraftswith wild-type forms of KRAS , NRAS , BRAF , and PIK3CA was compared with cetuximab response by one-way ANOVA and Bonferroni’s multiple comparisons test.”
Self-citationSartore-Bianchi, A., Martini, M., Molinari, F., Veronese, S., Nichelatti, M., Artale, S., Di Nicolantonio, F., Saletti, P., De Dosso, S., Mazzucchelli, L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2466 · Cited by 739
Self-citationJiao, Y., Pawlik, T. M., Anders, R. A., Selaru, F. M., Streppel, M. M., Lucas, D. J., Niknafs, N., Guthrie, V. B., Maitra, A., Argani, P., et al. (2013) · Nature Genetics · doi:10.1038/ng.2813 · Cited by 684
Self-citationActivation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0558 · Cited by 657
Self-citationMutations in a signalling pathway
Parsons, D. W., Wang, T.-L., Samuels, Y., Bardelli, A., Cummins, J. M., DeLong, L., Silliman, N., Ptak, J., Szabo, S., Willson, J. K. V., et al. (2005) · Nature · doi:10.1038/436792a · Cited by 599 · cited 1×
“Weandothershavepreviouslyidentifiedalterationsin IRS2 in CRCs and other tumour types, but no reports so far have linked the effects of these alterations to therapeutic sensitivity 14,23 .”
Self-citationFibroblast growth factors and their receptors in cancer
Wesche, J., Haglund, K., & Haugsten, E. M. (2011) · Biochemical Journal · doi:10.1042/bj20101603 · Cited by 534 · cited 2×
“FGFR1 is a known driver in human cancers 17 and has been reported to be amplified in different tumour types.”
Montagut, C., Dalmases, A., Bellosillo, B., Crespo, M., Pairet, S., Iglesias, M., Salido, M., Gallen, M., Marsters, S., Tsai, S. P., et al. (2012) · Nature Medicine · doi:10.1038/nm.2609 · Cited by 513 · cited 2×
“Interestingly, G465 is structurally adjacent to residue S492 that has been shown, when altered, to interfere with cetuximab binding 11 (Fig.”
Personalized genomic analyses for cancer mutation discovery and interpretation
Jones, S., Anagnostou, V., Lytle, K., Parpart-Li, S., Nesselbush, M., Riley, D. R., Shukla, M., Chesnick, B., Kadan, M., Papp, E., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa7161 · Cited by 415
Self-citationSomatic Mutations of EGFR in Colorectal Cancers and Glioblastomas
Barber, T. D., Vogelstein, B., Kinzler, K. W., & Velculescu, V. E. (2004) · New England Journal of Medicine · doi:10.1056/nejm200412303512724 · Cited by 315 · cited 1×
“Additionally, three out of four tumours with alterations in exon 20 of PIK3CA and four out of five tumours with protein truncating orhomozygousdeletionsof PTEN wereresistanttoanti-EGFRblockade.”
Self-citationLeary, R. J., Lin, J. C., Cummins, J., Boca, S., Wood, L. D., Parsons, D. W., Jones, S., Sjöblom, T., Park, B.-H., Parsons, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808041105 · Cited by 306
Self-citationHER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
Kavuri, S. M., Jain, N., Galimi, F., Cottino, F., Leto, S. M., Migliardi, G., Searleman, A. C., Shen, W., Monsey, J., Trusolino, L., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1211 · Cited by 302
Self-citationMisale, S., Arena, S., Lamba, S., Siravegna, G., Lallo, A., Hobor, S., Russo, M., Buscarino, M., Lazzari, L., Sartore-Bianchi, A., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007947 · Cited by 263
Self-citationWang, T.-L., Maierhofer, C., Speicher, M. R., Lengauer, C., Vogelstein, B., Kinzler, K. W., & Velculescu, V. E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202610899 · Cited by 219
Self-citationMarks, J. L., Gong, Y., Chitale, D., Golas, B., McLellan, M. D., Kasai, Y., Ding, L., Mardis, E. R., Wilson, R. K., Solit, D., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0099 · Cited by 211 · cited 1×
“Alterationsof MAP2K1 at the same or nearby residues have been previously described in various cancers, are adjacent to the catalytic domain, and have been shown to confer IL-3-independent cell growth in vitro , suggesting that this mutation may be functionally active 20 .”
Tol, J., Dijkstra, J. R., Klomp, M., Teerenstra, S., Dommerholt, M., Vink-Börger, M. E., van Cleef, P. H., van Krieken, J. H., Punt, C. J. A., & Nagtegaal, I. D. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.03.036 · Cited by 210
Switching on kinases: oncogenic activation of BRAF and the PDGFR family
Dibb, N. J., Dilworth, S. M., & Mol, C. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1434 · Cited by 179
Galimi, F., Torti, D., Sassi, F., Isella, C., Corà, D., Gastaldi, S., Ribero, D., Muratore, A., Massucco, P., Siatis, D., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3377 · Cited by 124
Self-citationZanella, E. R., Galimi, F., Sassi, F., Migliardi, G., Cottino, F., Leto, S. M., Lupo, B., Erriquez, J., Isella, C., Comoglio, P. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010445 · Cited by 117
Self-citationVoigt, M., Braig, F., Göthel, M., Schulte, A., Lamszus, K., Bokemeyer, C., & Binder, M. (2012) · Neoplasia · doi:10.1593/neo.121242 · Cited by 106
Koefoed, K., Steinaa, L., Søderberg, J. N., Kjær, I., Jacobsen, H. J., Meijer, P.-J., Haurum, J. S., Jensen, A., Kragh, M., Andersen, P. S., et al. (2011) · mAbs · doi:10.4161/mabs.3.6.17955 · Cited by 91 · cited 1×
“To explore whether EGFR inhibition by antibodies targeting epitopes far from G465 might overcome resistance, we used Pan-HER (Symphogen), a monoclonal antibody mixture that binds EGFR epitopes different from those recognized by cetuximab and panitumumab 28 (Extended Data Fig.”
Self-citationÅlgars, A., Lintunen, M., Carpén, O., Ristamäki, R., & Sundström, J. T. T. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.223 · Cited by 60 · cited 1×
“Two of these 22 tumours had somatic sequence changes in EGFR (G465R or G465E) affecting domain III of the extracellular portion of the receptor.”
Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA
Diaz, L. A., Sausen, M., Fisher, G. A., & Velculescu, V. E. (2013) · Oncotarget · doi:10.18632/oncotarget.1486 · Cited by 39
Self-citationPavlíček, A., Lira, M. E., Lee, N. V., Ching, K. A., Ye, J., Cao, J. Q., Garza, S. J., Hook, K. E., Ozeck, M., Shi, S. T., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0442-t · Cited by 37
LAS: A Software Platform to Support Oncological Data Management
Baralis, E., Bertotti, A., Fiori, A., & Grand, A. (2012) · Journal of Medical Systems · doi:10.1007/s10916-012-9891-6 · Cited by 35
Self-citationSomatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer
Moroni, M., Bianchi, A. S., Benvenuti, S., Artale, S. A., Bardelli, A., & Siena, S. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi356 · Cited by 32
Self-citationLeary, R. J., Cummins, J. M., Wang, T., & Velculescu, V. E. (2007) · Nature Protocols · doi:10.1038/nprot.2007.276 · Cited by 23
Self-citationSiena, S., Cutsem, E. V., Li, M., Jungnelius, U., Romano, A., Beck, R. E., Bencardino, K. B., Élez, E., Prenen, H., Sanchis, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062264 · Cited by 22 · cited 1×
“Using the approach previously described 37 , we analysed 24,334 somatic mutations (non-synonymous and synonymous single-base substitutions plus indels) identified in the protein coding sequence of 127 tumour graft samples, after samples with KRAS hotspot mutations (codons 12 or 13) and those with a…”
Self-citation
Cited by
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
“The response to current anti-EGFR therapy can be modified by factors such as: the type of somatic EGFR mutations, EGFR gene amplification, increased autocrine EGFR ligands, and mutations in EGFR signaling pathway proteins ERBB2, K-RAS, B-RAF, PI3KCA, PTEN, and BIM (reviewed in [375,379]).”
BackgroundConsensus molecular subtypes and the evolution of precision medicine in colorectal cancer
Dienstmann, R., Vermeulen, L., Guinney, J., Kopetz, S., Tejpar, S., & Tabernero, J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.126 · Cited by 1,021
Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016
“(3) You must attribute this AAM in the following format: Creative Commons BY-NC-ND license (http://creativecommons.”
BackgroundSelf-citationEvolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
Anagnostou, V., Smith, K. N., Forde, P. M., Niknafs, N., Bhattacharya, R., White, J., Zhang, T., Adleff, V., Phallen, J., Wali, N., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0828 · Cited by 896
“Acquisition of somatic resistance mutations is a common mechanism of therapeutic resistance to targeted therapies (23).”
BackgroundMethodSelf-citationHigh grade serous ovarian carcinomas originate in the fallopian tube
Labidi-Galy, S. I., Papp, E., Hallberg, D., Niknafs, N., Adleff, V., Noe, M., Bhattacharya, R., Novak, M., Jones, S., Phallen, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00962-1 · Cited by 759
Self-citation
Metadata
- Authors
- Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., Sausen, M., Phallen, J., Hruban, C. A., Tokheim, C., Niknafs, N., Nesselbush, M., Lytle, K., Sassi, F., Cottino, F., Migliardi, G., Zanella, E. R., Ribero, D., Russolillo, N., Mellano, A., Muratore, A., Paraluppi, G., Salizzoni, M., Marsoni, S., Kragh, M., Lantto, J., Cassingena, A., Li, Q. K., Karchin, R., Scharpf, R., Sartore-Bianchi, A., Siena, S., Diaz, L. A., Trusolino, L., & Velculescu, V. E.
- Affiliations
- Istituto Nazionale Biostrutture e Biosistemi (IT)
- Johns Hopkins University (US)
- Candiolo Cancer Institute (IT)
- Azienda Ospedaliero Universitaria San Giovanni Battista (IT)
- Symphogen (Denmark) (DK)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- University of Milan (IT)
- Corresponding author
- Bertotti, Andrea
- Trusolino, Livio
- Velculescu, Victor E.
- ORCID
- Bertotti, Andrea
- Papp, Eniko
- Jones, Siân
- Adleff, Vilmos
- Anagnostou, Valsamo
- Lupo, Barbara
- Sausen, Mark
- Phallen, Jillian
- Hruban, Carolyn A.
- Tokheim, Collin
- Niknafs, Noushin
- Nesselbush, Monica
- Sassi, Francesco
- Cottino, Francesca
- Migliardi, Giorgia
- Zanella, Eugenia R.
- Ribero, Dario
- Russolillo, Nadia
- Mellano, Alfredo
- Muratore, Andrea
- Salizzoni, Mauro
- Marsoni, Silvia
- Kragh, Michael
- Lantto, Johan
- Cassingena, Andrea
- Li, Qing Kay
- Karchin, Rachel
- Scharpf, Robert
- Siena, Salvatore
- Diaz, Luis A.
- Trusolino, Livio
- Velculescu, Victor E.
- Venue
- Nature
- Published
- 2015-09-30
- Volume
- 526
- Issue
- 7572
- Pages
- 263-267
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4878148
- OpenAlex
- W2102354469
- Cited by
- 479
- References
- 41
- Citations by year
- 2026: 16 · 2025: 28 · 2024: 37 · 2023: 35 · 2022: 47 · 2021: 50 · 2020: 47 · 2019: 59 · 2018: 56 · 2017: 57 · 2016: 43 · 2015: 3
- FWCI
- 23.15
- Type
- journal article
- Language
- en
- Update notices
- correction (2026-02-16)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (5r01ca121113-15)
- National Cancer Institute (R01-CA121113, CA-121113, P30CA006973)
- National Institute of General Medical Sciences (T32GM007057)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- EGFR inhibition, anti-EGFR antibody therapy, cetuximab, panitumumab, treatment resistance, primary resistance, somatic mutations, ERBB2, FGFR1, PDGFRA, MEK1, KRAS wild-type
- MeSH terms
- Cetuximab, Panitumumab, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Female, Humans, Mutation, Colorectal Neoplasms, Genome, Human, Proto-Oncogene Proteins p21(ras), Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, Receptor, Platelet-Derived Growth Factor alpha, Xenograft Model Antitumor Assays, Genomics, MAP Kinase Kinase 1, Mice, Receptor, Fibroblast Growth Factor, Type 1, Insulin Receptor Substrate Proteins, DNA Copy Number Variations, Molecular Targeted Therapy, Exome, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.